glucagon has been researched along with mosapride in 1 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (mosapride) | Trials (mosapride) | Recent Studies (post-2010) (mosapride) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 286 | 90 | 142 |
| Protein | Taxonomy | glucagon (IC50) | mosapride (IC50) |
|---|---|---|---|
| hepatocyte nuclear factor 4-alpha isoform 2 | Homo sapiens (human) | 4.18 | |
| perilipin-5 | Homo sapiens (human) | 1.315 | |
| perilipin-1 | Homo sapiens (human) | 1.196 | |
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | 1.2753 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.3966 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.4 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.7 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 3.6794 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 1 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.908 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.3966 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 3.8117 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 1 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.2959 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 4.7932 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.3056 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, K; Kamiyama, H; Masuda, K; Terauchi, Y; Togashi, Y | 1 |
1 trial(s) available for glucagon and mosapride
| Article | Year |
|---|---|
Mosapride citrate, a 5-HTâ‚„ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men.
Topics: Adult; Benzamides; Blood Glucose; Gastric Inhibitory Polypeptide; Gastrointestinal Agents; Gastrointestinal Tract; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Morpholines; Postprandial Period; Serotonin 5-HT4 Receptor Agonists; Up-Regulation | 2013 |